

SCIENTIFIC REPORTS

OPEN

Chemical profiling analysis of Maca using UHPLC-ESI-Orbitrap MS coupled with UHPLC-ESI-QqQ MS and the neuroprotective study on its active ingredients

Received: 03 November 2016

Accepted: 17 February 2017

Published: 17 March 2017

Yanyan Zhou^{1,*}, Peng Li^{2,*}, Adelheid Brantner³, Hongjie Wang¹, Xinbin Shu⁴, Jian Yang¹, Nan Si¹, Lingyu Han¹, Haiyu Zhao¹ & Baolin Bian¹

Lepidium meyenii (Maca), originated from Peru, has been cultivated widely in China as a popular health care food. However, the chemical and effective studies of Maca were less in-depth, which restricted its application seriously. To ensure the quality of Maca, a feasible and accurate strategy was established. One hundred and sixty compounds including 30 reference standards were identified in 6 fractions of methanol extract of Maca by UHPLC-ESI-Orbitrap MS. Among them, 15 representative active compounds were simultaneously determined in 17 samples by UHPLC-ESI-QqQ MS. The results suggested that Maca from Yunnan province was the potential substitute for the one from Peru. Meanwhile, the neuroprotective effects of Maca were investigated. Three fractions and two pure compounds showed strong activities in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced zebrafish model. Among them, 80% methanol elution fraction (Fr₅) showed significant neuroprotective activity, followed by 100% part (Fr₆). The inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) was a possible mechanism of its neuroprotective effect.

Maca (*Lepidium meyenii*), known as “Peruvian ginseng”¹, has been used as traditional health care food for over 2000 years in South America. According to hypocotyl colors, it was classified in black, purple and yellow varieties². In 1992, Maca was recommended as the safety edible food by Food and Agriculture Organization (FAO). After twenty years of development, it has been considered as one of the star products in the global health care market. Because of its various potential effects, in the early 21st century, Maca was introduced into China successfully and vigorously promoted the cultivation in Yunnan, Xinjiang and Tibet regions at high altitude similar to Peru.

Traditionally, Maca was always used in strengthening body, improving fertility and sexual function. Modern pharmacological studies displayed its effects on depression, rheumatism, premenstrual discomfort and menopausal symptoms³. Significantly, along with the increasing risk of neurodegenerative diseases, the neuroprotective effect of Maca has been attracting great concern. The discovery and screening of neuroprotective substances from Maca should be given high priority^{4–12}.

Since 2016, the price of Maca decreased dramatically in China. There were a couple of reasons for this. Firstly, a plenty of inferior products of Maca disturbed the market. Secondly, the basic study of Maca could not meet the requirement of market. Both of them came down to the absence of in-depth research of Maca, including the chemical profiling, the reasonable quality standard and the systematic effects evaluation¹³.

Previously, people mainly focused on the nutrient compositions in Maca, such as proteins, amino acids and fatty acids. However, the secondary metabolites were mainly responsible for its multiple functions. The alkaloids,

¹Institute of Chinese Materia Medica, Academy of Chinese Medical Sciences, Beijing, China. ²Institute of Chinese Medical Sciences, University of Macau, Macau, China. ³Institute of Pharmaceutical Sciences Pharmacognosy, University of Graz, Graz, Austria. ⁴Shandong Rosemed Biopharm LTC, Yanzhou, Shandong province, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to H.Z. (email: hyzhao@icmm.ac.cn) or B.B. (email: blbian@icmm.ac.cn)




Figure 1. The total ion chromatogram (TIC) of Maca.

glucosinolates and macaenes should be deserved close attention¹⁴. UHPLC-ESI-Orbitrap MS was the valid solution for the chemical analysis of secondary metabolites in Maca, which could provide accurate full MS and MS/MS fragments measurements of the target compounds with high sensitivity and precision. For quantitative analysis, UHPLC-ESI-QqQ MS could determine different types of constituents irrespective of their ultraviolet absorption and the degree of separation by dynamic multiple reaction monitoring (DMRM) method.

In terms of neuroprotective effects evaluation, the zebrafish models of neurodegenerative diseases has been recognized by increasing numbers of researchers^{15–20}. Since zebrafish embryos were susceptible to various toxins such as MPTP, which was used as an inducible model of neuronal loss. Transparency was also a unique attribute of zebrafish that permitted direct assessment of drug effects on the nervous system. Also, the other multiple advantages of zebrafish, such as small size, high fecundity and ease of phenotype recognition, made it well suited for high-throughput screening. Meanwhile, in the evaluation of neurodegenerative diseases, MPTP-induced zebrafish model generated a loss of dopaminergic neurons similar to the mid-brain lesion in the Parkinsonian patients²¹.

Generally, in the present study, a sensitive and accurate strategy was developed for the comprehensive chemical analysis of Maca firstly. UHPLC-ESI-Orbitrap MS and UHPLC-ESI-QqQ MS were employed for the qualitative and quantitative analysis respectively. Totally, 160 constituents were detected and identified from 6 fractions of Maca extract. Fifteen of them were selected for the quality control study. Furthermore, the neuroprotective effect of Maca was studied by MPTP-induced zebrafish model with dopaminergic neuronal loss. 80% methanol elution fraction (Fr₅) showed significant neuroprotective effects, followed by 100% part (Fr₆). Also, the inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) experiments were performed *in vitro*, which also supported the 80% methanol elution fraction (Fr₅) as the strongest neuroprotective fraction. Imidazole alkaloids, macamides and macaenes were predominant constituents in Fr₅. AChE and BuChE were regarded as the potential targets for the neuroprotective effects of Maca.

Results and Discussion

The chemical profiling analysis of Maca. The use of Octadecylsilyl gel (ODS gel) remarkably increased chromatographic peaks, and thus achieved the enrichment of minor constituents. UHPLC-ESI-Orbitrap MS was employed for the analysis. The element compositions of reference standards, unknown compounds and their MSⁿ fragments were calculated by accurate high resolution mass measurements. The total ion chromatogram (TIC) of Maca extract was shown in Fig. 1. In 6 enriched fractions, 160 ingredients were observed and identified, which were separated and enriched specifically according to their polarities. The main components in each fraction was illustrated as follows: Fr₁ (organic acids), Fr₂ (glucosinolates), Fr₃ (β-carboline alkaloids), Fr₄ (common amide alkaloids, macaridines), Fr₅ (mainly imidazole alkaloids, macamides, macaenes), Fr₆ (macamides).

Among them, 30 compounds were identified unambiguously by comparing with the retention time and MS data of reference standards. The other 130 constituents were deduced by their collision induced dissociation pathways together with literatures. Alkaloids, glucosinolates and macaenes were the major chemical ingredients of Maca.

Identification of alkaloids in Maca. Macamides, common amide alkaloids, macaridines, β-carboline alkaloids and imidazole alkaloids were five subtypes of characteristic alkaloids in Maca. As we knew, alkaloids always presented high sensitivity in the positive ion mode. Totally, 121 unknown alkaloids were identified.

A₅₄ and A₃₂ were two representatives of macamides, the fragmentation patterns of which were shown in Figs 2 and 3 respectively. In the MS/MS analysis of them, the diagnostic fragments of A₅₄ at *m/z* 268.2633 (C₁₇H₃₃NO) and 239.2368 (C₁₆H₃₀O) were yielded by neutral loss of phenyl group and the cleavage of amide bond respectively. The fragment ions of A₃₂ at *m/z* 290.2116 (C₁₉H₃₁NO) and 261.2214 (C₁₈H₂₈O) were produced by




Figure 2. The fragmentation patterns of N-benzylhexadecanamide (No. A₅₄).




Figure 3. The fragmentation patterns of N-(3-methoxybenzyl)-(9Z, 12Z, 15Z)-octadecatrienamamide (No. A₃₂).

losing N-3-methoxy phenyl group and the cleavage of amide bond respectively. The further loss of H₂O groups from C₁₆H₃₀O of A₅₄ and C₁₈H₂₈O of A₃₂ yielded the product ions at *m/z* 221.2265 (C₁₆H₂₈) and *m/z* 243.2093 (C₁₈H₂₆). Successively, the loss of CH₂ groups was also monitored in the further MS/MS fragmentations. The MS/MS spectra of A₃₂ and A₅₄ were shown in Figures S1 and S2 separately. Compound A₅₈ (*t_R* = 63.83 min) and A₅₅ (*t_R* = 62.23 min) gave [M + H]⁺ ions at *m/z* 360.3256 (C₂₄H₄₂NO) and *m/z* 402.3363 (C₂₆H₄₄NO₂) in the full mass spectra. In their MS/MS experiments, the fragment ions of A₅₈ at *m/z* 282.2792 (C₁₈H₃₆NO) and 253.2419 (C₁₇H₃₃O) were produced by neutral loss of phenyl group and the cleavage of amide bond respectively. Similarly, the fragment ions of A₅₅ at *m/z* 294.2792 (C₁₉H₃₆NO) and 265.2526 (C₁₈H₃₃O) were yielded by losing N-3-methoxy phenyl group and the cleavage of amide bond respectively. The fragment at *m/z* 235.2419 (C₁₇H₃₁) of A₅₈ and the fragment at *m/z* 247.2421 (C₁₈H₃₁) of A₅₅ were generated by the splitting of H₂O after the cleavage of amide bond. The successive loss of CH₂ groups was monitored in the further dissociation. The benzene ions were also detected in the MS/MS analysis of two compounds. Thus, A₅₈ and A₅₅ were identified as N-benzylheptadecanamide (Figure S3) and N-(3-methoxybenzyl)-(9Z)-octadecanamide (Figure S4). Furthermore, 64 macamides and common alkaloids (A₁-A₆₄) were deduced according to similar fragmentation pathways (Table S1).




Figure 4. Proposed fragmentation pathways of 3-benzyl-1,2-dihydro-N-hydroxypyridine-4-carbaldehyde (No. A₆₆).

As for macaridines, A₆₆ showed [M + H]⁺ ion at *m/z* 216.1019 (C₁₃H₁₄NO₂) in the full mass spectrum. The fragmentation pattern of A₆₆ was shown in Fig. 4. The [M + H - H₂O]⁺ ion at *m/z* 198.0915 (C₁₃H₁₄NO) was firstly determined in the MS/MS experiment. The further neutral loss of CO group generated the fragment ion at *m/z* 170.0965 (C₇H₁₀NO₂). And the fragment ion at *m/z* 91.0541 (C₇H₇) was yielded by losing C₅H₅N group.

The ESI-MS spectrum of A₆₅ (t_R = 24.33 min) showed a [M + H]⁺ ion at *m/z* 218.1175 (C₁₃H₁₆NO₂). The loss of H₂O group yielded [M + H - H₂O]⁺ ion at *m/z* 200.1279 (C₁₃H₁₄NO). The [M + H - C₆H₅]⁺ and [M + H - C₆H₉NO₂]⁺ ions at *m/z* 140.0708 (C₇H₁₀NO₂) and 91.0541 (C₇H₇) were found in the MS/MS spectrum, indicating that the further neutral loss of phenyl group and the existence of benzyl group. Thus, A₆₅ was deduced as 3-benzyl-1, 2-dihydro-N-hydroxypyridine-4-methoxy (Figure S5). The other 2 macaridines (A₆₆, A₆₇) were identified following the same dissociation pathways (Table S2).

Besides, the MS dissociation of some characteristic β-carboline alkaloids and imidazole alkaloids such as (1R, 3S)-1-methyltetrahydro-β-carboline-3-carboxylic acid (A₁₁₀) and 1, 3-dibenzyl-4, 5-dimethylimidazolium (A₈₂) were investigated as well. A₈₂ showed the representative fragments [M + H - benzyl]⁺ and [benzyl]⁺ at *m/z* 185.1075 and *m/z* 91.0541 according to the literature²². In line with the mass data and literatures^{23,24}, the cleavage of NH₃, C₂H₂, C₂O₂, C₂H₄ and CH₂ groups from the precursor ion of A₁₁₀ was detected.

In the MS/MS analysis of A₈₄ (t_R = 28.84 min), the [M + H]⁺ ion at *m/z* 305.2011 (C₂₁H₂₅N₂) was detected. The [M + H - C₇H₇]⁺ and C₇H₇⁺ ions were also found at *m/z* 213.1390 (C₁₄H₁₇N₂) and 91.0541 (C₇H₇). Besides, two fragments at *m/z* 199.12318 (C₁₃H₁₅N₂) and *m/z* 185.1074 (C₁₂H₁₃N₂) were assigned as the successive loss of CH₂ moieties. All the fragmentation pattern of A₈₄ revealed itself to be 1, 3-dibenzyl-2-ethyl-4, 5-dimethylimidazolium (Figure S6). The MS behaviors of 38 imidazole alkaloids (A₆₈-A₁₀₅) were in line with that of A₈₄ (Table S3).

The ESI-MS spectrum of A₁₁₁ (t_R = 18.21 min) showed a [M + H]⁺ ion at *m/z* 245.1284 (C₁₄H₁₇N₂O₂). In the MS/MS fragmentation, [M + H - H₂O]⁺ ion at *m/z* 227.1177 (C₁₄H₁₅N₂O) was detected. Another two fragments at *m/z* 167.0813 (C₈H₁₁N₂O₂) and *m/z* 153.0658 (C₇H₉N₂O₂) were generated from the neutral loss of phenyl and benzyl group from [M + H]⁺ ion respectively, which suggested that A₁₁₁ was (1R, 3S)-1-ethyltetrahydro-β-5,6-carboline-3-carboxylic acid (Figure S7). Sixteen β-carboline alkaloids (A₁₀₆-A₁₂₁) were also assigned following the same dissociation pathways (Table S4).

Identification of glucosinolates and acids in Maca. Glucosinolates and acids displayed the [M - H]⁻ ions with sufficient abundance in the negative ion mode. In agreement with literatures, the cleavage of SO₃, glucose, C₈H₇ON, C₈H₇NS, C₆H₁₂O₅S and H₂O groups was detected in the MS/MS spectra^{25,26}. Take G₅ as a reference compound for example (Fig. 5), the ESI-MS spectrum of G₅ (t_R = 14.96 min) showed a [M - H]⁻ ion at *m/z* 408.0423 (C₁₄H₁₉O₉NS₂). The [M - H - C₇H₇ - N = C = S]⁻ ion at *m/z* 259.0124 (C₆H₁₂O₉S) was observed in the MS/MS experiment. The further loss of H₂O from this obtained ion at *m/z* 241.0020 (C₆H₁₀O₈S) and the [M - H - C₇H₇ - N = C = O]⁻ ion at *m/z* 274.9896 (C₆H₁₂O₈S₂) were detected as well. All these three aforementioned ions were formed through intramolecular rearrangements, in which the sulfate group was transferred to the thioglucose moiety. Moreover, the ion at *m/z* 212.0020 (C₈H₇O₄NS) was deduced as the loss of the D-thioglucose group from [M - H]⁻ ion. The other two fragments at *m/z* 328.0852 (C₁₄H₁₉O₆NS) and 166.0331 (C₈H₇ONS) were assigned as the loss of SO₃ (80 Da) and further loss of glucose²⁶. Additionally, the loss of H₂O group was considered as the representative fragmentation pathway in acids (Table S5).

In the negative ion mode, 14 glucosinolates (Table S6) were detected and identified. Among them, 3 glucosinolates (G₃, G₅, G₈) and 5 acids (C₁-C₅) were isolated and characterized as reference standards.

G₁₁ (t_R = 21.30 min) was a classical compound with dominant amount, which showed [M - H]⁻ ion at *m/z* 450.0504 (C₁₆H₂₀O₁₀NS₂). The MS/MS spectrum produced [M - H - Glc]⁻ ion at *m/z* 287.0550 (C₁₀H₉O₅NS₂). The [M - H - SO₃]⁻ ion at *m/z* 370.0949 (C₁₆H₂₀O₇NS) and the [M - H - C₈H₇ON]⁻ ion at *m/z* 316.9993 (C₈H₁₃O₅S₂) were also found. The cleavages of C₈H₇NS from [M - H]⁻ ion was detected at *m/z* 301.0225 (C₈H₁₃O₁₀S). The further loss of H₂O group generated the fragment at *m/z* 283.0117 (C₈H₁₁O₉S). Meanwhile, the [M - H - C₈H₁₂O₅S]⁻ and [M - H - C₈H₁₂O₅S - H₂O]⁻ fragments at *m/z* 230.0121 (C₈H₈O₅NS) and *m/z* 212.0017 (C₈H₆O₄NS) were also observed. The product ion at *m/z* 166.0328 (C₈H₈ONS) were attributable to the breakage of C₈H₁₂O₆ group from C₁₆H₂₀O₇NS. All of the fragmentation patterns revealed G₁₁ as acetyl-benzylglucosinolate (Figure S8).

Identification of macaenes in Maca. As reported before, macaenes were also the characteristic compounds from Maca²⁷. In the present study, 11 macaenes were observed in the positive ion mode, among of which, 5-oxo-6E, 8E-octadecadienoic acid (M₇) has high content. M₇ demonstrated obvious fragments at *m/z* 277.2165 and *m/z* 259.2059, indicating the continuous loss of 2H₂O groups.




Figure 5. The fragmentation patterns of benzylglucosinolate (No. G₃).

M₉ ($t_R = 53.02$ min) exhibited $[M + H]^+$ ion at m/z 309.2418 (C₁₉H₃₃O₃) in full scan mass spectrum. Its MS/MS spectrum presented $[M + H - H_2O]^+$ fragment at m/z 291.2321 (C₁₉H₃₁O₂). The fragments of this obtained ion at m/z 277.2161 (C₁₈H₂₉O₂) and m/z 153.0911 (C₉H₁₃O₂) indicated the loss of CH₂ and C₁₀H₁₈ groups respectively. The fragment at m/z 125.0962 (C₈H₁₃O) was assigned as the cleavage of CO from C₉H₁₃O₂ group. In addition, the product ion at m/z 185.1174 (C₁₀H₁₇O₃) was detected clearly, which was attributed as the loss of C₉H₁₆ group from $[M + H]^+$ ion. Consequently, M₉ was putatively characterized as 5-oxo-6E, 8E-nineteencadienoic acid (Figure S9). The MS behaviors of M₁-M₁₁ were in line with that of M₉ (Table S7).

Identification of other compounds in Maca. Nine other compounds were detected and identified including flavonoids, organic esters, pyridine and benzylcyanide constituents (Table S8). For example, O₆ showed the loss of C₂H₄, C₃H₆, and C₉H₁₀O₂ clearly in the MS/MS spectrum, which was in accordance with Licochalcone A²⁸.

Quantitative analysis of samples. Ion polarity switching mode was adopted in the quantitative analysis. Glucosinolates and acids were determined in the negative ion mode, while others were detected in the positive ion mode.

Compounds	Regression equations	Linear ranges ($\mu\text{g}\cdot\text{mL}^{-1}$)	Correlation coefficients/r	Detection Limits ($\text{ng}\cdot\text{mL}^{-1}$)	Quantification Limits ($\text{ng}\cdot\text{mL}^{-1}$)
G ₅	$y = 0.98x + 0.40$	13.14~2628.87	0.9952	26.29	262.89
G ₃	$y = 5.43x + 7.39e^{-5}$	0.93~186.43	0.9997	18.64	186.43
G ₈	$y = 5.63x + 2.07e^{-3}$	0.24~23.80	0.9998	118.99	237.97
A ₅₂	$y = 0.21x + 0.10$	2.39~478.52	0.9990	4.79	4.79
A ₈	$y = 8.67x + 0.40$	0.18~35.14	0.9964	0.35	0.35
A ₅₄	$y = 1.14x + 5.67$	1.92~384.88	0.9951	3.85	3.85
O ₆	$y = 1.02x + 7.15e^{-3}$	5.65e ⁻² ~11.30	0.9989	0.11	0.11
A ₆₆	$y = 1.99x + 0.16$	0.30~60.14	0.9956	0.60	0.60
A ₆₇	$y = 0.62x + 2.83e^{-2}$	0.22~43.64	0.9960	0.44	4.36
A ₅	$y = 1.44x + 0.24$	0.45~90.38	0.9954	0.90	0.90
A ₄	$y = 3.67x + 6.86e^{-2}$	0.13~26.29	0.9985	0.26	0.26
C ₃	$y = 0.83x + 1.28e^{-2}$	0.72~1433.68	0.9974	143.37	286.74
C ₅	$y = 2.32x + 1.78e^{-3}$	0.82~8.25	0.9957	164.95	824.74
A ₁₂₁	$y = 3.42x + 1.68e^{-2}$	2.46e ⁻² ~4.91	0.9981	0.05	0.05
O ₉	$y = 1.38x + 5.48e^{-2}$	0.18~36.08	0.9985	0.36	0.36

Table 1. Linear equation, linear range, correlation coefficient and detection limits of 15 constituents.

Method validation. *Linearity of calibration curves, limit of detection (LOD) and limit of quantification (LOQ).* The internal standard method was employed to calculate the contents of 15 compounds in Maca. The standard solutions with internal standard were diluted with methanol to six different concentrations for the construction of calibration curves. The ratio of peak area to internal standard (Y_i/Y_s) of each analyte was plotted against the injection concentration (X , $\text{ng}\cdot\text{mL}^{-1}$). All the calibration curves indicated good linearity with determination coefficients (r) from 0.9951 to 0.9998. The limits of detection (LOD) and the limits of quantification (LOQ) were evaluated at a signal-to-noise ratio (S/N) of 3/1 and 10/1 respectively. The parameters of LOD and LOQ for each constituent in this experiment were from 0.05~164.95 $\text{ng}\cdot\text{mL}^{-1}$ and 0.05~824.74 $\text{ng}\cdot\text{mL}^{-1}$ (shown in Table 1^{29,30}).

Precision, stability and repeatability. The intra-day and inter-day precisions of the present method were calculated by analyzing the standard solution under the optimized experimental conditions. The RSD values of them were 0.41%~2.46% and 0.43%~2.71%. The RSD values of stability of each constituent in 48 hours at room temperature ($n = 6$) were 1.01%~2.84%. Furthermore, the sample solutions for Maca were prepared in parallel ($n = 6$) to evaluate the repeatability and achieved the RSD of 1.02%~2.63% (Table S9).

Recovery. The recovery was used to evaluate the accuracy of the method. Nine copies of 1 g Maca were taken for recovery test. The mixed standard solutions of 15 constituents were added according to three levels (1:0.8, 1:1, 1:1.2) respectively. The mixtures were treated as the preparation procedure of sample and analyzed using the method described above. Recovery (R) was calculated as $R = 100 \text{ (M}_{\text{measured}} - \text{M}_{\text{initial}}) / \text{M}_{\text{added}}$ ($\text{M}_{\text{measured}} = \text{measured amount in the recovery sample}$, $\text{M}_{\text{initial}} = \text{initial amount in the sample}$, $\text{M}_{\text{added}} = \text{amount in the standard solution used}$) for each compound. The average recovery rate of each constituent was 96.27%~98.89%, with the RSD values from 0.60% to 3.11% (Table S10), which met the requirements for the determination of 15 constituents in Maca.

Analysis of samples. This validated UHPLC-ESI-QqQ MS method was used for the quantification analysis of 15 constituents in 17 batches of Maca under the DMRM mode (Fig. 6). The analysis time was shortened to 15 minutes. Each constituent was calculated by their respective calibration curve, and the quantification results were shown in Table 2.

15 markers were identified unambiguously by comparing the retention times and transitions in DMRM mode of reference standards. Two internal standards were employed to guarantee the accuracy of determination. The polarity switching mode of QqQ MS was used to achieve the highest response intensities of each constituent. The quantification of Licochalcone A and 3-benzyl-1, 2-dihydro-N-hydroxypyridine-4-carbaldehyde was investigated as well, which were two representative constituents but with low contents in Maca.

The total amounts of investigated 15 compounds in Maca varied from 1.20% to 8.12%. Among them, glucosinolates (10.97~79.84 $\text{mg}\cdot\text{g}^{-1}$) and alkaloids (0.54~2.99 $\text{mg}\cdot\text{g}^{-1}$) were the predominant constituents. The contents of glucosinolates were significantly more than the other markers.

Significant variations were observed in different alkaloids. The contents of macamides were the highest with the amounts from 0.54 to 2.95 $\text{mg}\cdot\text{g}^{-1}$. Macamides were reported as one of the important secondary metabolites of Maca with neuroprotective, anti-fatigue, improving fertility and sexual functions effects. What's more, β -carboline alkaloids (A₁₂₁) and macaridines (A₆₆, A₆₇) were also detected in present analysis, the contents of which were 0~1.6 $\text{mg}\cdot\text{g}^{-1}$ and 1.47~72.61 $\text{mg}\cdot\text{g}^{-1}$. β -carboline alkaloids displayed neuroprotective effect²⁴.

In general, glucosinolates and β -carboline alkaloids in the samples from Peru were higher than those cultivated in China. However, the contents of organic acids, macaridines, common amide alkaloids, macamides in




Figure 6. The MRM chromatogram of mixed compounds (15 markers and 2 internal standards). 1. C_3 ; 2. C_5 ; 3. G_8 ; 4. G_5 ; 5. G_3 ; 6. A_4 ; 7. A_5 ; 8. A_{66} ; 9. A_{67} ; 10. A_8 ; 11. A_{121} ; 12. O_6 ; 13. O_9 ; 14. A_{52} ; 15. A_{54} . (A) 1–5: negative-DMRM mode; (B). 6–15: positive-DMRM mode.

Maca from China were higher than or similar to that from Peru. The results indicated that Maca cultivated in China especially in Yunnan province could be used as the potential substitute.

Among the Chinese samples, the contents of secondary metabolites in Yunnan province (Sample 7–Sample 17) were higher than those from the other two origins. The contents of effective constituents in the samples from Xinjiang province (Sample 1 and Sample 2) were relatively lower. Generally, the content tendency of different types constituents in Maca was similar to each other. Glucosinolates (G_3 , G_5 , G_8) and macamides (A_{52} , A_{54}) presented large amount (glucosinolates were 8–89 times than macamides), followed by organic acids (C_3 , C_5), macaridines (A_{66} , A_{67}), common amide alkaloids (A_4 , A_5), Licochalcone A (O_6).

In addition, Maca was always classified according to different hypocotyls colors in the market. In present study, a yellow and a purple Maca samples from the same growing environment and growth cycle were included in the analysis. Interestingly, the content of glucosinolates in 15 yellow Maca samples (Samples 1–5, 8–17) was higher than that in 2 purple Maca samples (Samples 6–7). However, from the data we collected, the types and contents of ingredients in purple and yellow Maca samples had no significant difference with each other, which was also in accordance with the literature³¹. Accurately, the geographical origin played a more important role than color. The results indicated that the contents of secondary metabolites in yellow Maca was in line with those in purple Maca generally. The quality discrepancy of them was not as significant as propagandized in market.

Also, the main components in different parts of Maca (roots and up-ground parts) were studied preliminary as well. The contents of active ingredients in the roots were higher than those in leaves. Three experimental samples were collected from the same Maca plant (Sample 12 and Leaves of Maca). To the best of our knowledge, in the biosynthetic pathways of macamides, benzylglucosinolate, free linoleic and linolenic acids, benzyl isothiocyanate and benzylamine were direct or indirect precursors^{32,33}. The accumulation of macamides was significantly associated with the contents of fatty acid and benzylamine. Thus, one of the important quality criterions of Maca was the levels of macamides and glucosinolates. In present study, both of them were higher in roots than those in leaves. The up-ground parts were regarded as the potential resources for the enrichment of the effective macamides.

In the cultivation of Maca, the harvest time, longitude and altitude affected its quality greatly. The present investigation provided a valuable strategy for the quality evaluation of Maca from their chemical profiling no matter the samples from different regions and varieties.

Neuroprotective effect screening of active fractions and pure compounds. Although, Maca has displayed the neuroprotective activity both *in vivo* and *in vitro*, its corresponding bioactive components and possible mechanism were still not clearly^{8,9,34}. In present study, the zebrafish embryos were treated with MPTP to form the DA neuronal loss model, which was always used for the neuroprotective evaluation. The DA neuronal loss site of zebrafish was located in the ventral diencephalic clusters (indicated by red brackets) (Fig. 7). As a result, by compared with the controls, MPTP model group resulted in 70% reduction of TH-positive neurons in the diencephalic area of the zebrafish embryo. The total Maca methanol extract displayed neuroprotective effect against MPTP-induced toxicity in zebrafish. Then, the activity evaluation of 6 fractions enriched by ODS column and 2 pure compounds was examined. The fractions and pure compounds were able to inhibit DA neuron loss by approximately 30–60% compared with the MPTP group. Consequently, Fr_4 – Fr_6 could increase the amount of dopamine neurons in different degrees with dose-dependent effect, especially for 80% methanol elution fraction (Fr_5) (Fig. 8). However, Fr_1 – Fr_3 showed no or little corresponding neuroprotective effects. The LC-MS chromatograms of Fr_4 – Fr_6 were shown in Figures S10–S12.

N-benzylhexadecanamide (A_{54}) and N-acetylbenzylamine (A_5) were two important active secondary metabolites in Maca with higher abundance. Because of their relative higher contents, A_5 and A_{54} were easily to be isolated from the plant. Thus, A_5 and A_{54} were chosen as the representative ingredients for the neuroprotective effect

Compounds	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Leaves of Maca
G ₅	1.35e ⁴	7.29e ⁴	1.35e ⁴	4.43e ⁴	1.19e ⁴	6.77e ⁴	3.72e ⁴	6.87e ⁴	4.90e ⁴	4.56e ⁴	1.05e ⁴	3.35e ⁴	4.15e ⁴	6.64e ⁴	4.66e ⁴	2.37e ⁴	7.46e ⁴	1.67e ⁴
G ₃	3.21e ³	4.30e ³	2.59e ³	1.61e ³	6.87e ²	2.50e ³	1.44e ³	3.16e ³	1.76e ³	2.02e ³	4.24e ²	1.20e ³	1.80e ³	3.17e ³	1.37e ³	9.30e ²	4.15e ³	6.28e ²
G ₈	50.39	646.70	612.04	282.16	104.27	455.12	371.59	576.75	496.56	400.90	90.58	309.11	368.97	1.13 e ³	418.06	433.26	1.04 e ³	220.77
A ₅₂	955.27	1.00 e ³	1.01 e ³	317.23	487.52	864.58	920.38	1.92 e ³	1.01 e ³	1.58 e ³	483.78	830.26	1.33 e ³	1.59 e ³	366.69	2.21 e ³	778.60	257.88
A ₈	2.26	1.52	2.48	—	0.81	—	12.07	0	0.95	1.03	1.21	1.39	1.01	—	0.88	1.42	1.54	1.47
A ₅₄	918.95	397.09	518.27	234.68	232.52	661.36	413.40	369.04	337.46	496.81	352.89	287.28	482.69	591.76	167.21	685.48	349.95	96.85
O ₆	0.32	—	0.32	—	0.28	—	—	0.40	—	—	—	—	—	0.29	—	0.89	—	—
A ₆₆	82.83	10.27	43.34	3.30	32.87	50.48	7.92	8.42	8.59	28.07	40.67	10.61	20.72	10.15	1.47	31.80	5.77	—
A ₆₇	12.81	2.56	8.41	—	9.48	11.15	2.25	2.29	2.71	9.01	12.76	3.40	7.08	2.29	—	12.04	1.65	—
A ₅	40.24	11.03	29.63	3.50	21.47	19.62	18.88	24.98	19.81	20.37	8.64	9.96	37.05	53.40	3.39	44.95	5.39	14.96
A ₄	25.13	27.59	16.06	0.10	8.00	52.99	4.40	12.89	5.51	3.37	10.28	9.11	2.30	6.71	3.66	3.42	14.19	0.69
C ₃	23.30	6.62	35.38	—	20.74	16.47	10.46	9.16	7.01	11.59	7.85	6.38	6.37	29.73	5.68	20.05	13.50	18.39
C ₅	78.85	35.08	143.64	21.92	124.84	187.08	67.09	90.60	43.11	144.54	72.13	66.90	60.85	101.40	86.34	206.56	237.07	595.44
A ₁₂₁	0.19	0.13	0.51	—	1.60	1.01	—	0.32	—	0.22	0.58	—	0.14	0.43	—	0.26	0.25	0.13
O ₉	3.51	2.60	2.42	1.16	4.12	2.65	2.61	3.76	2.45	2.54	2.80	2.13	3.03	3.86	0.99	2.05	2.94	—

Table 2. The contents of 15 compounds in 17 samples of Maca ($\mu\text{g}\cdot\text{g}^{-1}$, $n = 3$).




Figure 7. Representative pictures of Maca fractions and pure compounds against the dopaminergic neuron loss treated with MPTP in Zebrafish. DA neurons were examined in zebrafish by whole-mount immunostaining with an antibody against TH, the rate-determining enzyme involved in the synthesis of DA. Thus, TH⁺ neurons in the diencephalic area of the zebrafish brain were considered as DA neurons.

evaluation. Combination with chemical profiling analysis, common alkaloids and macaridines were predominant constituents in 50% methanol elution fraction (Fr₄). 80% methanol elution fraction (Fr₅) mainly contained imidazole alkaloids, macamides and macaenes. Macamides were also observed in 100% methanol elution fraction (Fr₆). Interestingly, both Fr₅ and Fr₆ contained N-benzylhexadecanamide (A₅₄) with high abundance. Therefore, A₅₄ was selected as the representative pure compound for the effective confirmatory experiment. As the results, at the dose of 30 and 10 $\mu\text{g}\cdot\text{mL}^{-1}$, A₅₄ could significantly prevent the MPTP-induced decrease in TH⁺ region area, and showed neuroprotective actions in a dose-dependent manner. Meanwhile, N-acetylbenzylamine (A₅) demonstrated noteworthy protections against MPTP-induced toxicity with dose-dependent manner, which was the major constituent in Fr₄ fraction. The results were in accordance with the neuroprotective properties of the pentane extract of Maca reported before. Macamides, a class of benzylated and 3-methoxybenzylated alkamides, were identified as the major characteristic effective compounds of Maca³⁵. Because of its excellent solubility profile, macamides could act on the endocannabinoid system and showed fatty acid amide hydrolase (FAAH)




Figure 8. The quantitative results of Maca fractions and pure compounds against the dopaminergic neuron loss treated with MPTP in Zebrafish. Quantitative analysis of TH⁺ neurons in zebrafish brain. Data are expressed as a percentage of the control group. Each bar represents mean \pm SD. #p < 0.05 vs. the control group; *p < 0.05 vs. and **p < 0.01 vs. the MPTP-treated group.

inhibitory activities⁵. In present study, A₅₄ also showed dose-dependent neuroprotective effect by restoring dopaminergic neuronal loss. The results inspired that Maca was available for the impairment of the endocannabinoid system in dopaminergic neurons, which was closely related to a serious of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and so on. Additional studies of macamides should be carried out on the mechanism of FAAH inhibition involving the endocannabinoid system³⁶. Further, macaridines, imidazole alkaloids and macaenes in Maca also should be concerned. Additionally, the results also demonstrated that zebrafish could be useful for the neuroprotective activity evaluation. The brain of zebrafish embryonic contained clusters of dopaminergic with the characteristics of inexpensive, low-maintenance and abundantly produce offspring. Furthermore, a significant inherent advantage was its transparency. Therefore, zebrafish could provide invaluable insights for large scale screening, drug discovery, modeling behavioral and functional parameters of neurodegeneration disorders and preclinical treatments^{37–43}.

Parkinson's disease (PD) was a progressive neurodegenerative disorder characterized by the selective loss of nigral dopaminergic neurons and a reduction in striatal dopaminergic fibers⁴⁴. MPTP was metabolized to MPP⁺, which generated a similar loss of dopaminergic neurons with corresponding Parkinsonian symptoms⁴⁵. Thus, we used zebrafish treated with MPTP as the neuronal loss model. Meanwhile, as reported in patients with Parkinson's disease, both the dopaminergic and cholinergic systems underwent degeneration, which led to deficits in dopamine and acetylcholine at synapses. As for the cholinergic system, MPTP also decreased the gene expression of choline acetyltransferase (ChAT) while increased the expression of acetylcholinesterase (AChE)⁴⁶. In present study, we attempted to bring new evidence supporting the potential neuroprotective action of Maca in PD, focusing on the interaction between dopaminergic and cholinergic systems. Dopamine was supposed to possess modulatory effect in cholinergic transmission, which played a critical role in modulating cortical cholinergic activity by GABAergic intracortical circuits⁴⁶. And the dopaminergic system might be dysfunctional in AD, which was possibly generated by the disrupting of the cholinergic system^{47,48}. Thus, after the evaluation of Maca on dopamine neuronal loss model in zebrafish by the method of *anti-tyrosine hydroxylase (TH) whole-mount immunostaining*, the AChE and BuChE inhibition activities of 6 fractions and pure compound were carried out. Collectively, these findings indicated that Maca showed neuroprotective activity through the synergistic effect of dopaminergic system and cholinergic system, which needed to be further validation.

Another important reason for the analysis of AChE and BuChE inhibition was from the structures of the neuroprotective chemicals. As we all know, the structural similarities of endocannabinoids and macamides indicated their potential neuroprotection effects. The purified macamides or its synthetic derivatives suggested highly possible activities on the endocannabinoid system⁴⁹. As we knew, the impairment of the endocannabinoid system in dopaminergic neurons would result in many neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, depression and schizophrenia^{50,51}. Meanwhile, dual FAAH/ChE inhibitors, with well-balanced nanomolar activities might be considered as new promising candidates for Alzheimer's disease treatment, which also suggested the close relationship between endocannabinoid system and cholinergic system⁵². This possible collaboration between cholinergic and dopaminergic neurotransmission in the midbrain raised the possibility of targeting both systems simultaneously to treat PD and AD in the future. Therefore, the preliminary analysis of AChE and BuChE were included in the manuscript. The *in vitro* AChE and BuChE inhibition assays showed (Table 3) that Fr₄ (IC₅₀ = 50.78 μ g.mL⁻¹), Fr₅ (IC₅₀ = 5.37 μ g.mL⁻¹) and Fr₆ (IC₅₀ = 15.77 μ g.mL⁻¹) displayed significant AChE inhibitory activity. Similarly, Fr₄ (IC₅₀ = 45.11 μ g.mL⁻¹), Fr₅ (IC₅₀ = 5.41 μ g.mL⁻¹) and Fr₆ (IC₅₀ = 23.39 μ g.mL⁻¹) showed significant BuChE inhibitory activity. The results were in accordance with those *in vivo* experiments. As the mutual constitute in Fr₅ and Fr₆, N-benzylhexadecanamide (A₅₄) was selected to validate this mechanism as pure compound, which also displayed high AChE (IC₅₀ = 14.23 μ g.mL⁻¹) and BuChE (IC₅₀ = 17.54 μ g.mL⁻¹) inhibitory activities. What's more, A₅₄ were reported as dual AChE/BuChE inhibitors without remarkable side effects^{53–55}. In conclusion, Fr₅ and macamides produced the healing efficacy by increasing the acetylcholine and butyrylcholine level in brain.

NO.	Samples	Acetylcholinesterase inhibition assay IC ₅₀ (μg.mL ⁻¹)	Butyrylcholinesterase inhibition assay IC ₅₀ (μg.mL ⁻¹)
0	Standard (eserin)	0.46	0.58
1	Total methanol extract	100.43	42.25*
2	Fr ₁	466.83	318.42
3	Fr ₂	663	281.68
4	Fr ₃	169.83	233.16
5	Fr ₄	50.78*	45.11*
6	Fr ₅	5.37**	5.41**
7	Fr ₆	15.77**	23.39**
8	A ₅₄	14.23**	17.54**

Table 3. The results of Acetylcholinesterase and Butyrylcholinesterase inhibition assays of Maca samples. *p < 0.05 and **p < 0.01.

Conclusions

In this paper, a high sensitive and efficient strategy for the integrating quality control of Maca was established. Alkaloids, glucosinolates, and macaenes were detected as the predominant secondary metabolites in this plant. Among them, five types of alkaloids were observed, including macamides, imidazole alkaloids, macaridine, β-carboline alkaloids and common amide alkaloids. According to the quantitative analysis of 15 major chemical markers in Maca, the contents variety of different origins, crust colors and different parts of plant were clarified. Meanwhile, the neuroprotective effects of 6 fractions against MPTP induced neurotoxicity zebrafish model were examined. 80% methanol elution fraction (Fr₅) and 100% methanol elution fraction (Fr₆) were regarded as the most effective neuroprotective parts. Both of these two parts contained macamides. The verification test by pure compounds also proved that alkaloids were the neuroprotective constituents in Maca. The inhibition of AChE and BuChE was one of the possible mechanisms. These findings suggested that Maca was a valuable health care food for the neurodegeneration disease such as Alzheimer Disease, Parkinson's disease and so on.

Methods

Chemicals and Reagents. Methanol for extraction was obtained from Honeywell Burdick and Jackson (Swedesboro, NJ, USA). HPLC grade acetonitrile was purchased from Merck Company (Rahway, NJ, USA). HPLC grade formic acid was provided by ROE Scientific Inc. (Delaware, USA). MPTP, Dimethyl Sulphoxide (DMSO), Trizma, 5,5'-Dithiobis (2-nitro-benzoic acid), Acetylthiocholine iodide (ATCI), AChE from *Electrophorus electricus* eel Type VI-S (AChE), S-Butyrylthiocholine iodide (BTCI), BuChE from equine serum (BuChE), Physostigmine (eserine) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals and reagents were of high analytical grade.

The reference standards were isolated and purified by authors, including m-methoxybenzylglucosinolate(G₃), benzylglucosinolate(G₅), p-hydroxybenzylglucosinolate(G₈), N-(3-methoxybenzyl)-hexadecanamide(A₅₂), N-benzylbenzamide(A₈), N-benzylhexadecanamide(A₅₄), LicochalconeA(O₆), 3-benzyl-1,2-dihydro-N-hydroxypyridine-4-carbaldehyde(A₆₆), (3-methoxybenzyl)-N-pyridine-4-carbaldehyde(A₆₇), N-acetylbenzylamine (A₅), 2-phenylacetamide(A₄), Nicotinic acid(C₃), Succinic acid(C₅), (1R,3S)-1-methyl-β-carboline-3-carbaldehyde(A₁₂₁), Dibutyl phthalate(O₉). Silica gel, RP-C₁₈ (200–300 mesh, Qingdao Marine Chemical Factory, Qingdao, China), sephadex LH-20 column chromatography and preparation liquid chromatography were used in the isolation. Their structures were identified by MS, NMR and UV spectra (Figure S13). 4-Aminohippuric acid (IS₁), Evodiamine(IS₂) were employed as the internal standards, which were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). The purities of all the reference standards were over 95%.

UHPLC-ESI-Orbitrap MS analysis and UHPLC-ESI-QqQ MS analysis. *Preparation of samples solutions.* 3 g powder of Maca was extracted under ultrasonic in 30 mL methanol for 30 min. After centrifugation at 12000 g for 10 min, the supernatant was condensed to 2 mL, and applied to an Octadecylsilyl gel column (ODS, 200 mL, 3.5 cm × 60 cm) eluted with 5%, 10%, 30%, 50%, 80%, 100% (800 mL) methanol. Each 800 mL of the elution was collected as one fraction⁵⁶. All the 6 fractions (Fr₁-Fr₆) were analyzed by LC-MS/MS and employed for neuroprotective evaluation of Maca.

Maca samples (fine powder) from different places (Table S11) were weighed 1 g and dissolved in 5 mL methanol. After ultrasonic extraction for 30 min, the samples were centrifuged at 12000 g for 10 min. Then the supernatant of each sample was transferred to a clean test tube.

Preparation of standard solutions. The 15 reference standards were dissolved in HPLC grade methanol to achieve a stock solution with concentration of 1.0 mg.mL⁻¹ for each compound respectively, then added corresponding volume according to their proportions in the sample and mixed. An internal standard stock solution was also prepared in a concentration of 0.92 mg.mL⁻¹ for IS₁ and 2.49 mg.mL⁻¹ for IS₂. The standard stock solutions were kept at 4 °C before analysis.

Analytical conditions. In qualitative analysis, the assay was performed using an ultimate 3000 hyperbaric liquid chromatography system coupled to a LTQ Orbitrap mass spectrometer *via* an ESI interface. The

Compounds	Precursor Ion → Product Ion/(<i>m/z</i>)	Collision Energy/V
G ₅	407.8 → 74.9; 96.9*	37; 24
G ₃	437.9 → 74.9; 97.0*	34; 34
G ₈	423.8 → 75.0; 96.9*	30; 30
A ₅₂	376.2 → 121.0*; 238.9	24; 18
A ₈	212.0 → 91.0*; 105.0	30; 12
A ₅₄	346.2 → 91.0*; 239.1	24; 24
O ₆	339.0 → 121.0*; 297.1	34; 18
A ₆₆	216.0 → 91.0; 198.0*	37; 6
A ₆₇	228.0 → 94.0; 200.0	21; 15
A ₅	150.0 → 65.0; 91.0*	46; 18
A ₄	136.0 → 65.0; 91.0*	40; 21
C ₃	121.9 → 50.8; 78.0*	30; 6
C ₅	116.9 → 73.0*; 78.9	6; 6
A ₁₂₁	211.0 → 169.0; 193.0*	30; 30
O ₉	279.1 → 149.0*; 205.1	15; 3

Table 4. Parameters of UHPLC-ESI-QqQ MS analysis for 15 constituents. *Quantitative ion.

chromatography system consisted of an autosampler, a diode array detector, a column compartment and two pumps. Xcalibur, Networks and Mass Frontier 7.0 software package were used for data collection and data analysis.

Liquid chromatographic separations of the analytes were performed by a Thermo AcclaimTM120 C18 column (250 mm × 2.1 mm, 3 μm). The mobile phase consisted of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B). The samples were eluted with the following linear gradient: 1% B at 0–5 min, 1–30% B at 5–20 min, 30–50% B at 20–30 min, 50–70% B at 30–40 min, 70–95% B at 40–60 min, 95% B at 60–80 min. The flow rate was 0.3 mL min⁻¹. The injection volume was 5 μL. The temperature-controlled column oven was set at 30 °C and the sampler was set at 4 °C.

The ESI source parameters were as follows: Both positive and negative ionization modes were used in the analysis. For positive mode, the capillary temperature was 350 °C, sheath gas (N₂) flow rate was 40 psi and aux gas flow rate was 10 psi, ion spray voltage was set at 3.5 kv. While for negative mode, the capillary temperature was 350 °C, sheath gas (N₂) flow rate was 35 psi and aux gas flow rate was 10 psi, ion spray voltage was set at -3.2 kv. In the FT cell, full MS scans were acquired in the range of *m/z* 50–1500 with a mass resolution of 30,000. The MS/MS and MS³ experiments were set as data dependent scan.

In the quantitative analysis, an Agilent 6490 A triple quadrupole LC-MS system (Agilent Corporation, MA, USA) equipped with G1311A quaternary pump, G1322A vacuum degasser, G1329A autosampler and G1316A therm was employed.

Chromatography was performed on a Thermo Hypersil Gold-C18 column (2.1 mm × 50 mm, 1.9 μm) with the column temperature at 30 °C. Mobile phase consisted of water containing 0.2% formic acid (A) and acetonitrile (B) and pumped at a flow rate of 0.3 mL.min⁻¹. A gradient program was used as follows: 1% B at 0–1 min, 1–5% B at 1–2 min, 5–10% B at 2–4 min, 10–50% B at 4–7 min, 50–90% B at 7–10 min, 90–100% B at 10–13 min, 100% B at 13–15 min. The injection volume was 2 μL.

Analytes were quantitated by monitoring the precursor-product combination in the DMRM mode using ion polarity switching mode. To ensure the desired abundance of each compound, the CE values and other parameters were optimized and illustrated as follows: cycle time, 300 ms; For positive mode, capillary voltage, 3 kv, nozzle voltage, 1.5 kv, Delta EMV(+), 200 v. For negative mode, capillary voltage, -2 kv, nozzle voltage, -1 kv, Delta EMV(-), 200 v. The optimized mass transition ion pairs (*m/z*) for analytes and the detection of the conditions of the compounds were shown in Table 4.

Neuroprotective effect screening of fractions and compounds in Maca. Stock solutions of MPTP (10 mg.mL⁻¹) were made by adding water directly to the bottle. MPTP was diluted in Holtfreter's solution to achieve final concentration of 200 μM.

The samples for neuroprotective effect of Maca in zebrafish including total extract, aforementioned 6 fractions and two pure compounds (A₅, A₅₄) were dissolved in DMSO to get stock solution according to their toxic limit. Nomifensine, a dopamine transporter (DAT) inhibitor as positive control, was dissolved in DMSO to get the concentration of 3 μM. The content of DMSO in solutions was not more than 0.5%.

The neuroprotective effect assessment was performed on zebrafish model treated with 200 μM MPTP. Wild-type zebrafish embryos (1 days post fertilization (dpf)) were treated with pure compounds or fractions in zebrafish model for 2 days. After treatment, *anti-tyrosine hydroxylase (TH) whole-mount immunostaining* was performed using literature reported method^{57,58}. Zebrafish were fixed in 4% paraformaldehyde in PBS for 5 h, rinsed, and stored at -20 °C in 100% ethanol. Briefly, fixed samples were blocked (2% lamb serum and 0.1% BSA in PBST) for 1 h at room temperature. A mouse monoclonal anti-TH antibody (1:200 diluted in blocking buffer, MAB318, Millipore) was used as the primary antibody and incubated with the sample overnight at 4 °C. The next

day, samples were washed 6 times with PBST (30 min each wash), followed by incubation with goat anti-mouse antibody (1: 500 diluted in blocking buffer, Alexa Fluor®, USA) as secondary antibody for 1 h at room temperature in the dark. After staining, zebrafish were flat-mounted with 3.5% methylcellulose and photographed.

The experimental results of each fraction and compound were obtained from the three zebrafish statistics. Every zebrafish was taken a picture and the gray scale was calculated by IMAGE J software. As a result, representative pictures of dopaminergic neurons in the zebrafish brain from different treatment groups were selected. TH⁺ neurons in the diencephalic area of the zebrafish brain were considered as DA neurons.

For quantification of neuronal area, the periphery of each cluster was outlined by manually tracing the edge. The area (Am²) of each enclosed region was measured, and the subsections were summed to give the total cluster area. Origin software (MicroCal Software, Inc.) was used to generate graphs. Statistical significance was obtained by performing one-way ANOVA test using SPSS software.

Quantitative analysis of TH⁺ neurons was examined in each treatment groups. Values were expressed as a percentage of the control. #p < 0.05 vs. control; *p < 0.05 and **p < 0.01 vs. MPTP group.

AChE and BuChE inhibition assay. A modified Elman's test was performed to investigate the AChE and BuChE inhibitory potency of fractions and compounds⁵⁹. The data was measured in Microtiter plates 96 wells (Sterilin Art, No.611F96) and recorded on 1420 multilabel counter (Perkin Elmer, Wallac Victor²). The solutions of enzyme (at 2.43 units.mL⁻¹ concentration) were prepared in Trizma buffer (7.09 mg.mL⁻¹, pH 8). The solutions of reference (eserin), pure compounds and fractions (20 μL each, at 0.025 to 1000 μg.mL⁻¹ concentration) in DMSO and BuChE/AChE (40 μL) were added to buffer (190 μL) and incubated at 25 °C for 5 min. DTNB (20 μL) and acetylthiocholine iodide (ATC) (20 μL) were added to enzyme-inhibitor mixture to investigate the reaction. The production of yellow anion was determined for 10 min at 405 nm. By using same methodology, similar solution of enzyme without the inhibitor was processed, which acted as a control. The blank measurement consisted of substrate (20 μL), DTNB (20 μL), DMSO (20 μL) and buffer (230 μL). The experiment was done triplicate. The percentage inhibition was calculated using the following equation:

$$\text{Inhibition\%} = \frac{\{(\text{Positive control}_A - \text{Blank}_A) - (\text{Sample}_A - \text{Blank}_A)\}}{(\text{Positive control}_A - \text{Blank}_A)}$$

A = absorption

Results were expressed as mean ± SD. Differences among the groups were subjected to a one-way ANOVA (analysis of variance) followed by Duncan's multiple range. Statistical significance was accepted when a p-value was less than 0.05.

Ethics statement. We confirm that all methods were carried out in accordance with relevant guidelines and regulations.

We confirm that all experimental protocols were approved by Medicine Ethics Committee in Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences.

References

- Leon, J. The "Maca" (*Lepidium meyenii*), A little known food plant of Peru. *Econ Bot* 122–127 (1963).
- Gustavo, F. G. *et al.* Maca (*Lepidium meyenii* Walp), A review of its biological properties. *Rev Peru Med Exp Salud Publica* 31, 100–105 (2014).
- Xiao, W. *et al.* Recent Advances in study of Peruvian *Lepidium meyenii* (maca). *World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica* 9, 102–106 (2007).
- Alejandro, P. F., Diane, N. & Timothy, J. M. Neuroprotective effects of *Lepidium meyenii* (Maca). *Annals of the New York Academy of Sciences* 1199, 77–85 (2010).
- Almukadi, H. *et al.* The macamide N-3-methoxybenzyl-linoleamide is a time-dependent fatty acid amide hydrolase (FAAH) inhibitor. *Mol Neurobiol* 48, 333–339 (2013).
- Wu, H. *et al.* Macamides and their synthetic analogs: Evaluation of *in vitro* FAAH inhibition. *Bioorg Med Chem* 21, 5188–5197 (2013).
- Robio, J. *et al.* Aqueous and hydroalcoholic extracts of Black Maca (*Lepidium meyenii*) improve scopolamine-induced memory impairment in mice. *Food Chem Toxicol* 45, 1882–1890 (2007).
- Rubio, J. *et al.* Effect of three different cultivars of *Lepidium meyenii* (Maca) on learning and depression in ovariectomized mice. *BMC Complement Altern M* 6, 23 (2006).
- Rubio, J. *et al.* Dose-response effect of black maca (*Lepidium meyenii*) in mice with memory impairment induced by ethanol. *Toxicol Mech Method* 21, 628–634 (2011).
- Rubio, J., Qiong, W. & Liu, X. M. Aqueous Extract of Black Maca (*Lepidium meyenii*) on memory impairment induced by ovariectomy in Mice. *Evid-based Compl Alt* 1–7 (2011).
- Megan, M. M. *et al.* Analysis of macamides in samples of Maca (*Lepidium meyenii*) by HPLC-UV-MS/MS. *Phytochem Anal* 16, 463–469 (2005).
- Haidu, Z. *et al.* Identification of endocannabinoid system-modulating N-alkylamides from *Heliopsis helianthoides* var. *scabra* and *Lepidium meyenii*. *J Nat Prod* 77, 663–1669 (2014).
- Nie, D. S. *et al.* The study of *Lepidium meyenii* (Maca) on sexual function and related health benefits. *J of Human Sexual* 22, 10–12 (2013).
- Bai, N. *et al.* Study on the composition and pharmacological effects of Cruciferous plants. *J Chinese Med Mat* 34, 1465–1468 (2011).
- Brian, P. W. & Randall, T. P. Zebrafish models of cerebrovascular disease. *J Cerebr Blood F Met*, 34, 571–577 (2014).
- Edor, K., Edna, B., Nathalie, C. & Pierre, D. Zebrafish models for the functional genomics of neurogenetic disorders. *BBA-biomembranes* 1812, 335–345 (2011).
- Lee, Y. *et al.* Improvement of pentylenetetrazol-induced learning deficits by valproic acid in the adult zebrafish. *Eur J Pharmacol* 643, 225–231 (2010).
- Lu, X. L. *et al.* Protective effects of puerarin against Aβ40-induced vascular dysfunction in zebrafish and human endothelial cells. *Eur J Pharmacol* 732, 76–85 (2014).
- Jeong, J. Y. *et al.* Functional and developmental analysis of the blood–brain barrier in zebrafish. *Brain Res Bull* 75, 619–628 (2008).
- Kim, Y. H. *et al.* Reduced neuronal proliferation by proconvulsant drugs in the developing zebrafish brain. *Neurotoxicol Teratol* 32, 551–557 (2010).

21. Hung, M. W. *et al.* From Omics to Drug Metabolism and High Content Screen of Natural Product in Zebrafish: A New Model for Discovery of Neuroactive Compound. *Evid-Based Compl Alt* 1–20 (2012).
22. Cui, B. L., Lin, B. L., He, K. & Zheng, Q. Y. Imidazole alkaloids from *Lepidium meyenii*. *J Nat Prod* **66**, 1101–1103 (2003).
23. Muhammad, I., Zhao, J. P. & Dunbar, C. Composition of the essential oil of *Lepidium meyenii*(Walp.). *Phytochemistry* **59**, 105–110 (2002).
24. Gustavo, F. G. & Cynthia, G. C. The Methyltetrahydro-Carbolines in Maca (*Lepidium meyenii*). *Evid-Based Compl Alt* **6**, 315–316 (2009).
25. Dini, I., Tenore, G. C. & Dini, A. Glucosinolates from Maca (*Lepidium meyenii*). *Biochem Syst Ecol* **30**, 1087–1090 (2002).
26. Cataldi, T. R. I., Lelario, F., Orlando, D. & Bufo, S. A. Collision-Induced Dissociation of the A + 2 Isotope Ion Facilitates Glucosinolates Structure Elucidation by Electrospray Ionization-Tandem Mass Spectrometry with a Linear Quadrupole Ion Trap. *Anal Chem* **82**, 5686–5696 (2010).
27. Céline, C. *et al.* Secondary metabolites in Maca as affected by hypocotyl color, cultivation history, and site. *Agron J* **102**, 431–439 (2010).
28. Cui, Y. M. Study on isolation, identification, efficacy and fingerprint of flavonoids from Licorice. Huazhong University of Science and Technology (2008).
29. Sun, Q. H. *et al.* Qualitative and quantitative analysis of the chemical constituents in Mahuang-Fuzi-Xixin decoction based on high performance liquid chromatography combined with time-of-flight mass spectrometry and triple quadrupole mass spectrometers. *Biomed Chromatogr* **30**, 1820–1834 (2016).
30. Yang, Y. *et al.* Chemical profiling and quantification of Chinese medicinal formula Huang-Lian-Jie-Du decoction, a systematic quality control strategy using ultra high performance liquid chromatography combined with hybrid quadrupole-orbitrap and triple quadrupole mass spectrometers. *J Chromatogr A* **1321**, 88–99 (2013).
31. Pan, Y., Zhang, J., Li, Hong, Wang, Y. Z. & Li, W. Y. Characteristic fingerprinting based on macamides for discrimination of maca (*Lepidium meyenii*) by LC/MS/MS and multivariate statistical analysis. *J Sci Food Agric* **96**, 4475–4483 (2016).
32. Eliana, E. *et al.* Bioactive maca (*Lepidium meyenii*) alkamides are a result of traditional Andean postharvest drying practices. *Phytochemistry* **116**, 138–148 (2015).
33. Pan, Y., Zhang, J., Li, H., Wang, Y. Z. & Li, W. Y. Simultaneous Analysis of Macamides in Maca (*Lepidium meyenii*) with Different Drying Process by Liquid Chromatography Tandem Mass Spectrometry. *Food Anal. Methods* **9**, 1686–1695 (2016).
34. Zhang, Z. J. *et al.* Examining the neuroprotective effects of protocatechuic acid and chrysin on *in vitro* and *in vivo* models of Parkinson disease. *Free Radical Bio Med* **84**, 331–343 (2015).
35. Choi, E. H. *et al.* Supplementation of standardized lipid-soluble extract from maca (*Lepidium meyenii*) increases swimming endurance capacity in rats. *J Funct Foods* **4**, 568–573 (2012).
36. Pino-Figueroa, A., Vu, H., Kelley, C. J. & Maher, T. J. Mechanism of action of *Lepidium meyenii* (Maca): an explanation for its neuroprotective activity. *Am J Neuroprotec Neuroregen* **3**, 87–92 (2011).
37. Enid, T. M. *et al.* Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. *Mol Brain Res* **141**, 128–137 (2005).
38. Cuevas, E. *et al.* AcetylL-carnitine protects motor neurons and Rohon-Beard sensoryneurons against ketamine-induced neurotoxicity in zebrafish embryos. *Neurotoxicol Teratol* **39**, 69–6 (2013).
39. Rosemberg, D. B. *et al.* Behavioral effects of taurine pretreatment in zebrafish acutely exposed to ethanol. *Neuropharmacol* **63**, 613–623 (2012).
40. Rosemberg, D. B. *et al.* Taurine Prevents Enhancement of Acetylcholinesterase Activity Induced by Acute Ethanol Exposure and Decreases the Level of Markers of Oxidative Stress in Zebrafish Brain. *Neuroscience* **171**, 683–692 (2010).
41. Eder, K., Edna, B., Nathalie, C. & Pierre, D. Zebrafish models for the functional genomics of neurogenetic disorders. *Biochim Biophys Acta* **1812**, 335–345 (2011).
42. Bretaud, S., Lee, S. & Guo, S. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease. *Neurotoxicol Teratol* **26**, 857–864 (2004).
43. Liu, J. C. *et al.* Necrosis inhibitor-5 (NecroX-5), attenuates MPTP-induced motor deficits in a zebrafish model of Parkinson's disease. *Genes Genom* **37**, 1073–1079 (2015).
44. Pan-Montojo, F. & Funk, R. H. Implications of Parkinson's Disease Pathophysiology for the Development of Cell Replacement Strategies and Drug Discovery in Neurodegenerative Disease. *CNS Neurol Disord-DR* **11**, 907–920 (2012).
45. Ming-Wai, H. *et al.* From Omics to Drug Metabolism and High Content Screen of Natural Product in Zebrafish: A New Model for Discovery of Neuroactive Compound. *Evidence-Based Complementary and Alternative Medicine* 1–20 (2012).
46. Hiliario, W. F. *et al.* Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease. *J Mol Neurosci* **60**, 453–464 (2016).
47. Degroot, A. & Treit, D. Septal GABAergic and hippocampal cholinergic systems interact in the modulation of anxiety. *Neuroscience* **117**, 493–501 (2003).
48. Nardone, R., Höller, Y., Thomschewski, A., Kunz, A. B., Lochner, P. & Golaszewski, S. Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL. *J Neural Transm* **121**, 1313–1320 (2014).
49. Martorana A. *et al.* Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer's Disease Patients. *Neuropsychopharm* **34**, 2323–2328 (2009).
50. Wu, H. *et al.* Macamides and their synthetic analogs: Evaluation of *in vitro* FAAH inhibition. *Bioorg Med Chem* **21**, 5188–5197 (2013).
51. Stelt, M. V. & Marzo, V. D. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders. *Eur. J. Pharmacol* **480**, 133 (2003).
52. Mazzola, J. C. *et al.* Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. *Learn Mem.* **16**, 332 (2009).
53. Montanari, S. *et al.* Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agent. *J med chem* **59**, 6387–6406 (2016).
54. Pan, L. *et al.* Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. *Bioorg & Med Chem Lett* **18**, 3790–3793 (2008).
55. Zhou, Y. Y. *et al.* Recent researching progress of *Lepidium meyenii* (Maca). *China Journal of Chinese Materia Medica* **40**, 4521–4530 (2015).
56. Yang, W. Z. *et al.* A strategy for efficient discovery of new natural compounds by integrating orthogonal column chromatography and liquid chromatography/mass spectrometry analysis: Its application in Panax ginseng, Panax quinquefolium and Panax notoginseng to characterize 437 potential new ginsenosides. *Anal Chim Acta* **739**, 56–66 (2012).
57. Zhang, Z. J., Cheang, L. C., Wang M. M. & Lee, S. M. Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. *Int J Mol Med* **27**, 195–203 (2011).
58. Bitzur, S., Kam, Z. & Geiger, B. Structure and distribution of N-cadherin in developing zebrafish embryos: morphogenetic effects of ectopic over-expression. *Dev Dynam* **201**, 121–136 (1994).
59. Wszelaki, N., Kuciun, A. & Kiss, A. K. Screening of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity. *Acta Pharmacol* **60**, 119–128 (2010).

Acknowledgements

This work was financially supported by the National Natural Science Fund Project (No. 81573967), Key Project at Central Government Level for Regulating Funds (No. 2060302), Beijing Nova Program and International Science & Technology Cooperation Program of China (No. 2014DFG32700). The source bull owned by Maca girl company was also to be appreciated for providing some samples.

Author Contributions

Y.Z. and P.L. performed experiments and H.Z. assisted in data analysis. Y.Z. analyzed data and wrote the paper. B.B., H.Z. and A.B. contributed to study design and overall supervision. H.W., X.S., J.Y., N.S. and L.H. discussed the results and commented on the manuscript. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Zhou, Y. *et al.* Chemical profiling analysis of Maca using UHPLC-ESI-Orbitrap MS coupled with UHPLC-ESI-QqQ MS and the neuroprotective study on its active ingredients. *Sci. Rep.* **7**, 44660; doi: 10.1038/srep44660 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017